Hypertension: Update
|
|
- Dustin Pope
- 5 years ago
- Views:
Transcription
1 Hypertension: Update Meenakshi A Bhalla MD,FACC Associate Professor of Medicine Director Preventive Cardiology Advanced Heart Failure and Transplant Cardiology University of Kentucky Faculty Disclosure None relevant. 1
2 Introduction Why are we still talking about hypertension? Guidelines Discrepancy How low is too low? Define Resistant Hypertension What is the data, how to treat it? Introduction Most common reason for office visits and use of prescription medications. NHANES ( ) estimated 29-31% of adults with hypertension. Approx million Americans over the age 20 years have hypertension. US trends in prevalence, awareness, treatment, and control of hypertension, JAMA 2010; 303:2043. Mean systolic and diastolic blood pressure in adults aged 18 and over in the United States, Natl Health Stat Report 2011; :1. 2
3 Prevalence of Hypertension in United States Egan BM, Zhao Y JAMA 2010; 303:2043 CV Mortality Risk Doubles with Each 20/10 mm Hg BP Increment* CV mortality risk /75 135/85 155/95 175/105 SBP/DBP (mm Hg) *Individuals aged years, starting at BP 115/75 mm Hg.CV, cardiovascular; SBP, systolic blood pressure; DBP, diastolic blood pressurelewington S, et al. Lancet. 2002; 60: JNC VII. JAMA
4 IHD Rates by SBP, DBP, and Age IHD Mortality (Floating Absolute Risk and 95% CI) A: Systolic Blood Pressure Age at risk: years years years years years IHD Mortality (Floating Absolute Risk and 95% CI) B: Diastolic Blood Pressure Age at risk: years years years years years Usual SBP (mm Hg) Usual DBP (mm Hg) Lewington et al. Lancet. 2002;360: Stroke mortality rates by SBP, DBP and Age Data from Prospective Studies Collaboration, Lancet 2002; 360:
5 Cumulative absolute risk of CVD at five years Reference: Non diabetic, Non smoking, 50 yo Female with TC 154 mg/dl, HDL 62 mg/dl Jackson R, Lawes CM, etal. Lancet 2005; 365:434 Trends in the awareness, treatment & control of high blood pressure in adults in the United States Data for adults yo of age with SBP 140 mm of Hg and/or DBP 90 mm of Hg Adapted from: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, JAMA 2003; 289:2560, and from US Trends in Prevalence, Awareness, Treatment, and Control of Hypertension , JAMA 2010; 303:
6 Potential reasons for low rates of blood pressure control 1. Access to healthcare and medications 2. Lack of adherence with long-term therapy 3. Therapeutic inertia 6.Wang TJ, Vasan RS. Epidemiology of uncontrolled hypertension in the United States. Circulation 2005; 112: Egan BM et al. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension 2012; 59:1124. JNC 7 Classification of Hypertension 6
7 JNC 8 Hypertension Guideline Algorithm Adult aged 18 years with HTN Implement lifestyle modifications Set BP goal, initiate BP lowering medication based on algorithm General Population (no diabetes or CKD) Diabetes or CKD present Initial Drugs of Choice for Hypertension ACE inhibitor (ACEI) Angiotensin receptor blocker (ARB) Thiazide diuretic Calciumchannel blocker (CCB) Age 60 years Age < 60 years All Ages Diabetes present No CKD BP Goal < 150/90 Nonblack Initiate thiazide, ACEI, ARB, or CCB, alone or in combo BP Goal < 140/90 Black Initiate thiazide or CCB, alone or combo At blood pressuregoal? No Reinforce lifestyle and adherence Titrate medications to maximum doses or consider adding another medication (ACEI, ARB, CCB, Thiazide) At blood pressure goal? No No BP Goal < 140/90 All Ages and Races CKD present with or without diabetes BP Goal < 140/90 Initiate ACEI or ARB, alone or combo w/another class Reinforce lifestyle and adherence Add a medication class not already selected (i.e. beta blocker, aldosterone antagonist, others) and titrate above medications to max (see back of card) At blood pressuregoal? Reinforcelifestyle and adherence Titrate meds to maximum doses, add another med and/or refer to hypertension specialist Yes Yes Yes Strategy A B C Continue tx and monitoring Description Start one drug, titrate to maximum dose, and then add a second drug. Start one drug, then add a second drug before achieving max dose of first Begin 2 drugs at same time, as separate pills or combination pill. Initial combination therapy is recommended if BP is greater than 20/10mm Hg above goal Lifestyle changes: Smoking Cessation Control blood glucose and lipids Diet Eat healthy (i.e., DASH diet) Moderate alcohol consumption Reduce sodium intake to no more than 2,400 mg/day Physical activity Moderate to vigorous activity 3 4 days a week averaging 40 min per session. Reference: James PA, Ortiz E, et al evidence-based guideline for the management of high blood pressure in adults: (JNC8). JAMA Feb 5;311(5): Indication Heart Failure Post MI/ClinicalCAD CAD Diabetes CKD Recurrent strokeprevention Pregnancy Compelling Indications Treatment Choice ACEI/ARB + BB + diuretic + spironolactone ACEI/ARB AND BB ACEI, BB, diuretic, CCB ACEI/ARB, CCB, diuretic ACEI/ARB ACEI, diuretic labetolol (first line), nifedipine, methyldopa Hypertension Treatment Beta 1 Selective Beta blockers possibly safer in patients with COPD, asthma, diabetes, and peripheral vascular disease: metoprolol bisoprolol betaxolol acebutolol Drug Class Agents of Choice Comments Diuretics HCTZ mg, chlorthalidone mg, indapamide mg triamterene 100mg K+ sparing spironolactone 25 50mg, amiloride 5 10mg, triamterene 100mg furosemide 20 80mg twice daily, torsemide 10 40mg ACEI/ARB ACEI: lisinopril, benazapril, fosinopril and quinapril 10 40mg, ramipril 5 10mg, trandolapril 2 8mg ARB: candesartan 8 32mg, valsartan mg, losartan mg, olmesartan 20 40mg, telmisartan 20 80mg Beta Blockers Calcium channel blockers Vasodilators metoprolol succinate mg and tartrate mg twice daily, nebivolol 5 10mg, propranolol mg twice daily, carvedilol mg twice daily, bisoprolol 5 10mg, labetalol mg twice daily, Dihydropyridines: amlodipine 5 10mg, nifedipine ER 30 90mg, Non dihydropyridines: diltiazem ER mg, verapamil mg 3 times daily or ER mg hydralazine mg twice daily, minoxidil 5 10mg Monitor for hypokalemia Most SE are metabolic in nature Most effective when combined w/ ACEI Stronger clinical evidence w/chlorthalidone Spironolactone gynecomastia and hyperkalemia Loop diuretics may be needed when GFR <40mL/min SE: Cough (ACEI only), angioedema (more with ACEI), hyperkalemia Losartan lowers uric acid levels; candesartan may prevent migraine headaches Not first line agents reserve for post MI/CHF Cause fatigue and decreased heart rate Adversely affect glucose; mask hypoglycemic awareness Cause edema; dihydropyridines may be safely combined w/ B blocker Non dihydropyridines reduce heart rate and proteinuria Hydralazine and minoxidil may cause reflex tachycardia and fluid retention usually require diuretic + B blocker terazosin1 5mg, doxazosin1 4mg given at bedtime Alpha blockersmay cause orthostatic hypotension Centrally acting clonidine mg twice daily, methyldopa mg twice daily Clonidine available in weekly patch formulation for Agents resistant hypertension guanfacine 1 3mg Reference: James PA, Ortiz E, et al evidence based guideline for the management of high blood pressure in adults: (JNC8). JAMA Feb 5;311(5):
8 Comparison of International Guidelines on HTN Goals (mm Hg) HTN Guideline Controversy; Age at which the blood pressure goal should be increased to less than 150/90 mm of Hg Blood Pressure Management PSAP 2016 Treatment Of Hypertension in Patients with CAD; ACC/AHA guideline recommendation 1. <140/90 mm Hg reasonable target for the secondary prevention of cardiovascular events in patient with hypertension and CAD ( Class IIa; level of evidence B) 2. Lower target BP (<130/80 mm of Hg) may be appropriate in some individuals with CAD, previous MI, CVA or CAD risk equivalents ( Class IIb; level of evidence B) 3. Patients with elevated DBP and CAD with evidence of myocardial ischemia, BP should be lowered slowly, and caution advised in decreasing DBP<60 mm Hg in any patient with diabetes or age >60 yrs. ( Class IIa; level of evidence C) A scientific statement from the A scientific statement from the AHA/ACC/ASH. Circulation
9 Antihypertensive Therapy Recommendations for Patients with Ischemic Heart Disease Treatment of hypertension in patients with coronary artery disease. A scientific statement from the AHA/ACC/ASH. Circulation 2015 How low is the Target?? 9
10 Clinical Trial Evidence of Lower SBP Goals is Unclear ACCORD BP question: Does a strategy targeting systolic blood pressure (SBP) <120 mm Hg reduce CVD events compared to a strategy targeting SBP <140 mm Hg in 4,700 participants with type 2 diabetes at high risk for CVD events? Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. The ACCORD Study Group. N Engl J Med 2010; 362: Acaa ACCORD Results are Mixed Outcome Intensive Events (%/yr) Standard Events (%/yr) HR (95% CI) P CVD (Primary) 208 (1.87) 237 (2.09) 0.88 ( ) 0.20 Cardiovascular Deaths 60 (0.52) 58 (0.49) 1.06 ( ) 0.74 Total Stroke 36 (0.32) 62 (0.53) 0.59 ( ) 0.01 Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. The ACCORD Study Group. N Engl J Med 2010; 362:
11 ACCORD Adverse Events Adverse Events Intensive Standard N (%) N (%) P value Serious AE 77 (3.3) 30 (1.3) < Hypotension 17 (0.7) 1 (0.04) < Syncope 12 (0.5) 5 (0.2) 0.10 Bradycardia or Arrhythmia 12 (0.5) 3 (0.1) 0.02 Hyperkalemia 9 (0.4) 1 (0.04) 0.01 Renal Failure 5 (0.2) 1 (0.04) 0.12 egfr ever <30 ml/min/1.73m 2 99 (4.2) 52 (2.2) <0.001 Any Dialysis or ESRD 59 (2.5) 58 (2.4) 0.93 Dizziness on Standing 217 (44) 188 (40) 0.36 Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. The ACCORD Study Group. N Engl J Med 2010; 362: ACCORD- Summary No difference in the primary outcome composite of nonfatal MI, nonfatal stroke or CVD death. Secondary outcome of nonfatal and fatal stroke was improved in the intensively treated verses standard groups (numbers of events small 32 Int vs 62 Std) Side effects of syncope and hypotension was greatest in the intensively treated group (2.6 fold) Hypokalemia more common in the intensively treated group Same number in both groups progressed to ESRD End of study intensively treated group had lower GFR than standard group Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. The ACCORD Study Group. N Engl J Med 2010; 362:
12 SPRINT Research Question Examine effects of more intensive high blood pressure treatment than recommended Randomized Controlled Trial Target Systolic BP Total N= 9,361 Intensive Treatment Goal SBP < 120 mm of Hg N= 4,678 Standard Treatment Goal SBP < 140 mm of Hg N= 4,683 Median follow up 3.26 years SPRINT Res. Group. N Engl J Med 2015;373: Inclusion Criteria 50 years old SBP mm of Hg ( treated or untreated) Additional cardiovascular disease( CVD) risk - Clinical or subclinical CVD (excluding stroke) - CKD, defined as egfr ml/min/1.73 m2 - Framingham Risk Score for 10-year CVD risk 15% Exclusion Criteria Stroke Diabetes mellitus Polycystic kidney disease Congestive heart failure ( symptoms or EF<35%) Proteinuria >1 g per day CKD with egfr < 20 ml/min/1.73 m² ( MDRD) Adherence concerns - Age 75 years SPRINT Res. Group. N Engl J Med 2015;373:
13 SPRINT Primary Outcome and its Components Event Rates and Hazard Ratios SPRINT Res. Group. N Engl J Med 2015;373: Serious Adverse Events (SAE) During Follow-up SPRINT Res. Group. N Engl J Med 2015;373:
14 Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged 75 Years: A Randomized Clinical Trial Objective: To evaluate the effects of intensive (<120 mm Hg) vs standard(<140 mm Hg) SBP in patients 75 years with hypertension but without diabetes. Study Design: Patients 75 years who participated in SPRINT. Study duration Conclusions: Among ambulatory adults aged 75 years or older, treating to an SBP target of less than 120 mm Hg compared with an SBP target of less than 140 mm Hg resulted in significantly lower rates of fatal and nonfatal major cardiovascular events and death from any cause. Williamson JD et al. JAMA 2016;315: Summary Primary composite outcome (myocardial infarction, acute coronary syndrome, stroke, CHF, CV death) decreased 25% with intensive Rx. All cause mortality significantly lower in intensive Rx group: HR 0.73%; 95% CI 0.60 to 0.90; P= Hypotension, syncope, electrolyte abnormalities, and renal injury all higher in intensive Rx group (but not injurious falls). Application of results dependent on clinical judgment, tolerance of Rx, avoidance of associated problems, probable limitation to 4 BP medications. Fewer patients to meet SPRINT goals vs but will have CV events. + Same intensive BP Rx benefits adults 75 years with CV events. # *SPRINT Res. Group. N Engl J Med 2015;373: Ko MJ et al. J Am Coll Cardiol 2016;67: # Williamson JD et al. JAMA 2016;315:
15 Resistant Hypertension Defined as either a BP of 140/90 mm of Hg while using optimally dosed antihypertensive agents from 3 different drug classes( including a diuretic); or blood pressure that requires 4 or more medications to achieve control Differentiate from Pseudo resistance - Inaccurate BP measurements - Poor adherence to BP medications - Suboptimal antihypertensive therapy i.e inadequate doses or exclusion of diuretic. - White coat resistance ( 35% in Spanish study- well controlled via ambulatory monitoring) Causes Of True Resistant Hypertension Extracellular volume expansion Increased sympathetic activation Ingestion of substances ex NSAIDs/stimulants Secondary or contributing causes of hypertension. 15
16 Treatment; General Principles Identify and treat secondary hypertension Stop medications that raise the blood pressure Out-of-office blood pressure monitoring Non-pharmacologic therapy Pharmacological Therapy Diuretics: Persistent volume expansion contributes to resistant hypertension, even among patients who have been on conventional doses of thiazides. Mineralocorticoid Receptor Antagonists: provide significant antihypertensive benefit when added to existing multiple-drug regimens in patients with resistant hypertension. Gaddam KK et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 2008; 168:1159. Chapman N et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007; 49:
17 EXPERIMENTAL THERAPIES Catheter-based radiofrequency ablation of renal sympathetic nerves ( renal denervation) has not been established in patients with resistant hypertension A blinded randomized trial (SYMPLICITY-HTN-3) failed to demonstrate benefit. EXPERIMENTAL THERAPIES Electrical stimulation of carotid sinus baroreceptors- or baroreflex activation therapy (BAT), may decrease blood pressure in patients with resistant HTN. Rheos Pivotal Trial failed in two of its five primary endpoints, it remains unapproved by the FDA for the indication of resistant hypertension in the United States. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: Bisognano JD etal J Am Coll Cardiol. 2011;58(7):765 17
18 Differences in LV mechanics drive differential response to therapy in HFpEF and HFrEF Margaret M. Redfield et alpflugers Arch Jun; 466(6): Conclusions There is Much Established Benefit from the Treatment of Hypertension. The age at which the goal BP< 150/90 mm of Hg remains controversial. Selection of the Optimal Regimen Requires Experience, Judgement, Trial/Error. There is diminishing support for starting with β-blocker. Aggressive blood pressure target of 120/80 mm of Hg safe in carefully monitored patients. Direct renal artery surgery has not had good results. 18
19 Lifestyle Modifications Not at goal BP <140/90, or <130/80 for diabetes, CKD or CAD, or <120/80 for LV dysfunction Initial Drug Choices No Compelling Indications Stage 1 HTN 1. Thiazides for most 2. Consider ACEI, ARB, BB, CCB or combo Stage 2 HTN Two-drug combo for most; usually thiazide and ACEI, ARB, BB, or CCB Compelling Indications Drugs for compelling indications; others as needed 19
Hypertension (JNC-8)
Hypertension (JNC-8) Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! The 8 th Joint
More informationWhat in the World is Functional Medicine?
What in the World is Functional Medicine? An Introduction to a Systems Based Approach of Chronic Disease Meneah R Haworth, FNP-C Disclosure v I am a student of the Institute for Functional Medicine. They
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%
More informationMODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk
MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More informationManaging Hypertension in Diabetes Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park.
Managing Hypertension in Diabetes 2015 Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park Case Scenario Mike M is a 59 year old man with type 2 diabetes managed
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Prevalence 29%; Blacks 33.5% About 72.5% treated; 53.5% uncontrolled (>140/90) Risk for poor control: Latinos, Blacks, age 18-44 and 80,
More informationManaging Hypertension in 2016
Managing Hypertension in 2016: Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More informationDifficult to Treat Hypertension
Difficult to Treat Hypertension According to Goldilocks JNC 8 Blood Pressure Goals (2014) BP Goal 60 years old and greater*- systolic < 150 and diastolic < 90. (Grade A)** BP Goal 18-59 years old* diastolic
More information8/20/2018. Objectives. What is hypertension? cont. What is hypertension? Epidemiology cont. Epidemiology
Objectives Hypertension (high blood pressure): Clinical Pearls for the Pharmacy Technician Tanya Schmidt PharmD, RPh Director of Central Operations at Thrifty White Pharmacy North Dakota Board of Pharmacy
More informationHypertension Management: A Moving Target
9:45 :30am Hypertension Management: A Moving Target SPEAKER Karol Watson, MD, PhD, FACC Presenter Disclosure Information The following relationships exist related to this presentation: Karol E. Watson,
More information7/7/ CHD/MI LVH and LV dysfunction Dysrrhythmias Stroke PVD Renal insufficiency and failure Retinopathy. Normal <120 Prehypertension
Prevalence of Hypertension Hypertension: Diagnosis and Management T. Villela, M.D. Program Director University of California, San Francisco-San Francisco General Hospital Family and Community Medicine
More informationManagement of Hypertension
Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal
More informationImproving Outcomes for Hypertension
Spectrum of Health September 2017 Improving Outcomes for Hypertension Highlights: Recommendations of the Eighth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment
More informationPreventing and Treating High Blood Pressure
Preventing and Treating High Blood Pressure: Finding the Right Balance of Integrative and Pharmacologic Approaches Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Blood Pressure
More informationHypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute
Hypertension Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension 2017 Classification BP Category Systolic Diastolic Normal 120 and 80 Elevated
More informationWe are delighted to have Dr. Roetzheim with us today to discuss Managing Hypertension in Older Adult Patients.
Richard Roetzheim, MD, MSPH is Professor and Chair, Department of Family Medicine at the University of South Florida Morsani College of Medicine. Dr. Roetzheim has considerable experience leading NIH funded
More informationModern Management of Hypertension
Modern Management of Hypertension Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Hypertension Prevalence
More informationHypertensionTreatment Guidelines. Michaelene Urban APRN, MSN, ACNS-BC, ANP-BC
HypertensionTreatment Guidelines Michaelene Urban APRN, MSN, ACNS-BC, ANP-BC Objectives: Review the definition of the different stages of HTN. Review the current guidelines for treatment of HTN. Provided
More informationManagement of Lipid Disorders and Hypertension: Implications of the New Guidelines
Management of Lipid Disorders and Hypertension Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine
More informationAntihypertensive Agents
Antihypertensive Agents Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 7, 08, presented by Ezra Levy, Pharm.D! Usual Dose,
More informationHypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic
Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered
More informationModern Management of Hypertension: Where Do We Draw the Line?
Modern Management of Hypertension: Where Do We Draw the Line? Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Blood Pressure
More informationIntroductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs
Introductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs Blood Pressure Normal = sys
More informationHypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures
Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, 2015 William C. Cushman, MD Professor, Preventive Medicine, Medicine, and Physiology University
More informationHypertension in the Era of ACC/AHA: Practice Changing Evidence and Recommendations
Hypertension in the Era of ACC/AHA: Practice Changing Evidence and Recommendations Gerald W. Smetana, M.D., MACP Division of General Medicine Beth Israel Deaconess Medical Center Professor of Medicine
More informationHypertension 2015: Recent Evidence that Will Change Your Practice
Hypertension 2015: Recent Evidence that Will Change Your Practice Gerald W. Smetana, M.D. Division of General Medicine Beth Israel Deaconess Medical Center Professor of Medicine Harvard Medical School
More informationHypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
More informationHypertension Update 2009
Hypertension Update 2009 New Drugs, New Goals, New Approaches, New Lessons from Clinical Trials Timothy C Fagan, MD, FACP Professor Emeritus University of Arizona New Drugs Direct Renin Inhibitors Endothelin
More informationUpdate in Hypertension
Update in Hypertension Eliseo J. PérezP rez-stable MD Professor of Medicine DGIM, Department of Medicine UCSF 20 May 2008 Declaration of full disclosure: No conflict of interest (I have never been funded
More informationHypertension Management Controversies in the Elderly Patient
Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationMANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION
Management of Hypertension: Treatment Thresholds and Medication Selection Robert B. Baron, MD MS Professor and Associate Dean Declaration of full disclosure: No conflict of interest Presentation Goals
More informationHypertension Update. Mayo Clinic 90 th Annual Clinical Reviews November 2 nd and 16 th, 2016
Mayo Clinic 90 th Annual Clinical Reviews November 2 nd and 16 th, 2016 Hypertension Update Vincent J. Canzanello, M.D. Consultant, Division of Nephrology and Hypertension Professor or Medicine College
More informationHypertension and Cardiovascular Disease
Hypertension and Cardiovascular Disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic,
More informationTreating Hypertension from
Treating Hypertension from Initiation to Resistance: A Case Study Approach Michelle Krause, MD Division of Nephrology University of Arkansas for Medical Sciences Central Arkansas Veteran s Healthcare System
More informationManagement of High Blood Pressure in Adults
Management of High Blood Pressure in Adults Based on the Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC8) James, P. A. (2014, February 05). 2014 Guideline for Management
More informationHeart Failure Clinician Guide JANUARY 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2018 Introduction This evidence-based guideline summary is based on the 2018 National Heart Failure Guideline.
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationDifficult-to-Control & Resistant Hypertension. Anthony Viera, MD, MPH, FAHA Professor and Chair
Difficult-to-Control & Resistant Hypertension Anthony Viera, MD, MPH, FAHA Professor and Chair Objectives Define resistant hypertension Discuss evaluation strategy for patient with HTN that appears difficult
More informationHypertension diagnosis (see detail document) Diabetic. Target less than 130/80mmHg
Hypertension diagnosis (see detail document) Non-diabetic Diabetic Very elderly (older than 80 years) Target less than 140/90mmHg Target less than 130/80mmHg Consider SBP target less than 150mmHg Non-diabetic
More informationAdult Blood Pressure Clinician Guide June 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Blood Pressure Clinician Guide June 2018 Adult Blood Pressure Clinician Guide June 2018 Introduction This Clinician Guide is based on the 2018
More informationDISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE
ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE DISCLOSURES Editor-in-Chief- Nephrology- UpToDate- (Wolters Klewer) Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA 1 st Annual Internal
More informationSection 3, Lecture 2
59-291 Section 3, Lecture 2 Diuretics: -increase in Na + excretion (naturesis) Thiazide and Related diuretics -decreased PVR due to decreases muscle contraction -an economical and effective treatment -protect
More informationThe New Hypertension Guidelines
The New Hypertension Guidelines Joseph Saseen, PharmD Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Disclosure Joseph Saseen reports no conflicts
More informationHypertension Update. Sarah J. Payne, MS, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy UNT System College of Pharmacy
Hypertension Update Sarah J. Payne, MS, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy UNT System College of Pharmacy Introduction 1/3 of US adults have HTN More prevalent in non-hispanic
More information4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?
HYPERTENSION TARGETS: WHAT DO WE DO NOW? MICHAEL LEFEVRE, MD, MSPH PROFESSOR AND VICE CHAIR DEPARTMENT OF FAMILY AND COMMUNITY MEDICINE UNIVERSITY OF MISSOURI 4/4/17 DISCLOSURE: MEMBER OF THE JNC 8 PANEL
More informationHypertension Pharmacotherapy: A Practical Approach
Hypertension Pharmacotherapy: A Practical Approach Ronald Victor, MD Burns & Allen Chair in Cardiology Director, The Hypertension Center Associate Director, The Heart Institute Hypertension Center 1. 2.
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic
1 U.S. Department of Health and Human Services National Institutes of Health Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker
More informationNew Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant
More informationDr Narender Goel MD (Internal Medicine and Nephrology) Financial Disclosure: None, Conflict of Interest: None
Dr Narender Goel MD (Internal Medicine and Nephrology) drnarendergoel@gmail.com Financial Disclosure: None, Conflict of Interest: None 12 th December 2013, New York Visit us at: http://kidneyscience.info/
More informationHypertension Management - Summary
Who should have blood pressure assessed? Hypertension Management - Summary All patients over the age of 40 years, every 1-3 years in order to determine their cardiovascular risk (ie. Framingham Risk Score)
More informationCombination Therapy for Hypertension
Combination Therapy for Hypertension Se-Joong Rim, MD Cardiology Division, Yonsei University College of Medicine, Seoul, Korea Goals of Therapy Reduce CVD and renal morbidity and mortality. Treat to BP
More informationAPPENDIX D: PHARMACOTYHERAPY EVIDENCE
Página 1 de 7 APPENDIX D: PHARMACOTYHERAPY EVIDENCE Table D1. Outcome Trials of Antihypertensive Agents Study Drug Regimen N Duration Primary Outcomes Remarks Antihypertensive Therapy vs Placebo SHEP 1991
More informationWhat s In the New Hypertension Guidelines?
American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the
More informationBy Prof. Khaled El-Rabat
What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating
More informationTreating Hypertension in Individuals with Diabetes
Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any
More informationJared Moore, MD, FACP
Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner
More informationHypertension Update. Objectives 4/28/2015. Beverly J. Mathis, D.O. OOA May 2015
Hypertension Update Beverly J. Mathis, D.O. OOA May 2015 Objectives Learn new recommendations for BP treatment goals Approach to hypertension in the office Use of hypertensive drugs, and how to tailor
More informationHeart Failure Clinician Guide JANUARY 2016
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2016 Introduction This evidence-based guideline summary is based on the 2016 National Heart Failure Guideline.
More informationNetwork Hypertension Algorithm
Network Hypertension Algorithm Content Review and Approval: This document is subject to review, revision, and (re)approval by the Clinical Integration and Oversight Committee (CIOC) annually and following
More informationSTANDARD treatment algorithm mmHg
STANDARD treatment algorithm 130-140mmHg (i) At BASELINE, If AVERAGE SBP 1 > 140mmHg If on no antihypertensive drugs: Start 1 drug: If >55 years old / Afro-Caribbean: Calcium channel blocker (CCB) 2 If
More informationHypertension: JNC-7. Southern California University of Health Sciences Physician Assistant Program
Hypertension: JNC-7 Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! Reference Card
More informationAntihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Antihypertensive Agents Part-2 Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Agents that block production or action of angiotensin Angiotensin-converting
More informationGuide to the New Hypertension Guidelines
Guide to the New Hypertension Guidelines LCDR J. Garrett Sims, PharmD, BCPS Advanced Practice Pharmacist Crow/Northern Cheyenne Hospital Hypertension St Disclosures None Objectives Describe the new hypertension
More informationTreating Hypertension in 2018: What Makes the Most Sense Today?
Treating Hypertension in 2018: What Makes the Most Sense Today? Daniel Blanchard, MD Professor of Medicine UC San Diego Cardiovascular Center La Jolla, California 1 2 Speaker Disclosures Consultant and/or
More informationDisclosures. Learning Objectives. Hypertension: a sprint to the finish Ontario Pharmacists Association 1
Disclosures I have no current or past relationships with commercial entities I have received a speaker s fee from the Ontario Pharmacists Association for this learning activity Laura Tsang PharmD Sunnybrook
More informationHypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B)
Practice Guidelines and Principles: Guidelines and principles are intended to be flexible. They serve as reference points or recommendations, not rigid criteria. Guidelines and principles should be followed
More informationVA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005
VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 1 Any adult in the health care system 2 Obtain blood pressure (BP) (Reliable,
More informationDISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
More informationsympatholytics sympatholytics sympatholytics
sympatholytics sympatholytics sympatholytics CNS-ACTING SYMPATHOPLEGICS Sympathetic brain signals Doesn t affect baroreceptor reflex (no orthostatic hypotension) Methyldopa α-methylne crosses BBB (+) α-adrenoreceptors
More informationHypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town
Hypertension targets: sorting out the confusion Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town Historical Perspective The most famous casualty of this approach was the
More informationObjectives. Describe results and implications of recent landmark hypertension trials
Hypertension Update Daniel Schwartz, MD Assistant Professor of Medicine Associate Medical Director of Heart Transplantation Temple University School of Medicine Disclosures I currently have no relationships
More informationLong-Term Care Updates
Long-Term Care Updates August 2015 By Darren Hein, PharmD Hypertension is a clinical condition in which the force of blood pushing on the arteries is higher than normal. This increases the risk for heart
More informationNew Hypertension Guidelines: How Lower Blood Pressure Targets Affect Medication Safety
New Hypertension Guidelines: How Lower Blood Pressure Targets Affect Medication Safety Diana Isaacs, PharmD, BCPS, BC-ADM, CDE Clinical Pharmacy Specialist Cleveland Clinic Andrew Straw, PharmD, BC-ADM
More informationHypertension and the 2017 Guidelines Meeting the Targets in Small Groups. Lisa Ivy APRN
Hypertension and the 2017 Guidelines Meeting the Targets in Small Groups Lisa Ivy APRN The 2017 Guideline is an Update to JNC7 New information regarding BP related risk of CVD Ambulatory BP monitoring
More informationHypertension Controversies: SPRINTing to New Goals
Hypertension Controversies: SPRINTing to New Goals Diana Isaacs, PharmD, BCPS, BC-ADM, CDE Clinical Pharmacy Specialist Cleveland Clinic Lauren Wolfe, PharmD Primary Care Clinical Specialist Cleveland
More informationManagement of Hypertension in Women
Management of Hypertension in Women Eliseo J. Pérez-Stable MD Professor of Medicine DGIM, Department of Medicine July 1, 2013 Declaration of full disclosure: No conflict of interest (I have never been
More informationGuide to the New Hypertension Guidelines. LCDR J. Garrett Sims, PharmD, BCPS Crow/Northern Cheyenne Hospital
Guide to the New Hypertension Guidelines LCDR J. Garrett Sims, PharmD, BCPS Crow/Northern Cheyenne Hospital Disclosures None Objectives Describe the new hypertension staging and blood pressure goals and
More informationFactors Involved in Poor Control of Risk Factors
Factors Involved in Poor Control of Risk Factors Patient compliance Clinical inertia Health Care System structure 14781 M Limitations of Formal Studies Selection of patients Recruitment and follow-up alter
More informationHypertension and Diabetes Should we be SPRINTING or Reaching an ACCORD?
Hypertension and Diabetes Should we be SPRINTING or Reaching an ACCORD? Suzanne Oparil, MD Distinguished Professor of Medicine, Professor of Cell, Developmental and Integrative Biology Director, Vascular
More informationHypertension JNC 8 (2014)
Hypertension JNC 8 (2014) Renewed: February 2018 Updated: February 2015 Comparison of Seventh Joint National Committee (JNC 7) vs. Eighth Joint National Committee (JNC 8) Hypertension Guidelines Methodology
More informationHypertension CHAPTER-I CARDIOVASCULAR SYSTEM. Dr. K T NAIK Pharm.D Associate Professor Department of Pharm.D Krishna Teja Pharmacy College, Tirupati
CHAPTER-I CARDIOVASCULAR SYSTEM Hypertension SUB: PHARMACOTHERAPEUTICS-I CODE:T0820006 Dr. K T NAIK Pharm.D Associate Professor Department of Pharm.D Krishna Teja Pharmacy College, Tirupati Hypertension
More informationSystolic Blood Pressure Intervention Trial (SPRINT)
09:30-09:50 2016.4.15 Systolic Blood Pressure Intervention Trial (SPRINT) IN A NEPHROLOGIST S VIEW Sejoong Kim Seoul National University Bundang Hospital Current guidelines for BP control Lowering BP
More informationCOMPLEX HYPERTENSION. Anita Ralstin, FNP-BC Next Step Health Consultant, LLC
COMPLEX HYPERTENSION Anita Ralstin, FNP-BC Next Step Health Consultant, LLC Incidence Of Hypertension About 70 million American adults have high blood pressure. About 33% of the population Only 52% have
More informationHTN talk_l Davis_ /28/2018
1 2 GUIDELINES PUBLISHED AHEAD OF PRINT NOV 13, 2017 = SAME DAY AS PUBLIC PRESENTATION LESLIE L DAVIS, PHD, RN, ANP-BC, FPCNA, FAANP, FAHA The New Guidelines Have Been Published! Whelton PK, Carey RM,
More informationManaging HTN in the Elderly: How Low to Go
Managing HTN in the Elderly: How Low to Go Laxmi S. Mehta, MD, FACC The Ohio State University Medical Center Assistant Professor of Clinical Internal Medicine Clinical Director of the Women s Cardiovascular
More informationState of the art treatment of hypertension: established and new drugs. Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland
State of the art treatment of hypertension: established and new drugs Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland First line therapies in hypertension ACE inhibitors AT
More informationUnderstanding the importance of blood pressure control An overview of new guidelines: How do they impact daily current management?
Understanding the importance of blood pressure control An overview of new guidelines: How do they impact daily current management? Slides presented during CDMC in Almaty, Kazakhstan on Saturday April 12,
More informationBlood Pressure Targets: Where are We Now?
Blood Pressure Targets: Where are We Now? Diana Cao, PharmD, BCPS-AQ Cardiology Assistant Professor Department of Clinical & Administrative Sciences California Northstate University College of Pharmacy
More informationHYPERTENSION: UPDATE 2018
HYPERTENSION: UPDATE 2018 From the Cardiologist point of view Richard C Padgett, MD I have no disclosures HYPERTENSION ALWAYS THE ELEPHANT IN THE EXAM ROOM BUT SOMETIMES IT CHARGES HTN IN US ~78 million
More informationAntihypertensive drugs SUMMARY Made by: Lama Shatat
Antihypertensive drugs SUMMARY Made by: Lama Shatat Diuretic Thiazide diuretics The loop diuretics Potassium-sparing Diuretics *Hydrochlorothiazide *Chlorthalidone *Furosemide *Torsemide *Bumetanide Aldosterone
More informationClinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital
Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8 Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Objectives Review the Eighth Joint National Committee (JNC
More informationManagement of Hypertension. Ahmed El Hawary MD Suez Canal University
Management of Hypertension Ahmed El Hawary MD Suez Canal University Minimal vs. Optimal Care Resources more than science affect type of care and level of management. what is possible (minimal care) and
More informationUpdate on Current Trends in Hypertension Management
Friday General Session Update on Current Trends in Hypertension Management Shawna Nesbitt, MD Associate Dean, Minority Student Affairs Associate Professor, Department of Internal Medicine Office of Student
More informationJNC-8. (Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure- 8) An Update on Hypertension Guidelines
JNC-8 (Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure- 8) An Update on Hypertension Guidelines Derrick Sorweide, DO Assistant Professor of Family Medicine,
More informationThe Latest Generation of Clinical
The Latest Generation of Clinical Guidelines: HTN and HLD Dave Brackett Clinical Guideline Purpose Uniform approach Awareness of key details Diagnosis Treatment Monitoring Evidence based approach Inform
More informationReframe the Paradigm of Hypertension treatment Focus on Diabetes
Reframe the Paradigm of Hypertension treatment Focus on Diabetes Paola Atallah, MD Lecturer of Clinical Medicine SGUMC EDL monthly meeting October 25,2016 Overview Physiopathology of hypertension Classification
More informationPhysician/Clinic Collaborative Practice Agreement
Physician/Clinic Collaborative Practice Agreement Effective October 1, 2010, Connecticut Senate Bill 428 (PA 10-117) extends to all settings and medical conditions the opportunity for licensed pharmacists
More information